Neotigason (Acitretin)

Acitretin binds to nuclear retinoic acid and retinoid X receptors in skin cells, altering gene transcription that controls keratinocyte differentiation and proliferation. This normalises epidermal growth, reduces hyperkeratosis, and provides anti‑inflammatory effects on the skin.

The specific dose of Neotigason is determined by the prescribing physician based on the severity of the condition, patient weight, and clinical response. Dosage adjustments are made during treatment to balance efficacy and safety.

Acitretin is classified as pregnancy category X. It is contraindicated in pregnancy because it can cause severe birth defects. Women of child‑bearing potential must use effective contraception during treatment and for at least three years after stopping. Breastfeeding is also not recommended.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with biologic agents, Acitretin is an oral retinoid that does not require injection and has a different safety profile. It is often used when biologics are unsuitable or as part of combination therapy. Unlike methotrexate, it does not cause bone marrow suppression but carries a higher risk of teratogenicity and lipid abnormalities.

Neotigason should be stored at room temperature, below 25 °C, in its original packaging. Protect the tablets from moisture, excessive heat and direct sunlight to maintain stability and potency.

Neotigason is taken orally, usually once daily with a meal or a glass of milk to improve absorption and reduce gastrointestinal irritation. The exact timing and whether it is taken with food should follow the prescribing clinician’s instructions.

The most serious risks include teratogenicity (birth defects), severe liver toxicity, marked hyperlipidaemia, and rare cases of pseudotumour cerebri (increased intracranial pressure). Patients should be monitored regularly for liver function, lipid levels and any neurological symptoms.

Neotigason should not be used by pregnant women, women planning pregnancy, or those who cannot ensure effective contraception for the required period. It is also contraindicated in patients with severe liver disease, uncontrolled hyperlipidaemia, or known hypersensitivity to retinoids.